window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Neurology

  • Central Nervous System,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Zilucoplan accepted for eligible myasthenia gravis patients in NHS Scotland

    Zilucoplan has been accepted for restricted use in NHS Scotland [...]

    August 11, 2026
  • Central Nervous System,Digital & Data,Medical devices

    Natus expands AI-powered EEG analysis across Europe

    Natus has expanded access to its AI-powered EEG analysis tool [...]

    July 22, 2026
  • Clinical & Regulatory,Medical devices,Research & Development,Therapeutic Areas

    Alamar launches blood-based eMTBR-Tau assay for Alzheimer’s disease research

    Alamar Biosciences has launched what it describes as the first [...]

    July 8, 2026
  • Advanced Therapies,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Skyhawk reports encouraging 12-month Huntington’s disease data for SKY-0515

    Skyhawk Therapeutics has reported encouraging 12-month results from its ongoing [...]

    June 6, 2026
  • Digital & Data,Drug Discovery & Development

    Promise Bio launches grant to support translational epiproteomics in biotech research

    Promise Bio has launched the Frontier Epiproteomic Innovation Grant, providing [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth

    Veristat, a global clinical research organization (CRO) and consultancy specializing [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    New Alzheimer’s guideline recommends blood biomarkers for more accessible diagnosis

    In a significant shift for Alzheimer’s care, the Alzheimer’s Association [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    MHRA approves Biogen’s tofersen for ultra-rare genetic form of motor neurone disease

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    SpliceBio secures $135 Million series B to advance dual-AAV therapy for Stargardt Disease

    Funding will support clinical development of SB-007 and expand pipeline [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Calibre secures CQC registration for nationwide AI health service
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Pharmaceuticals and therapeutics, Research & Development
  • Cyllene gene therapy for bladder disorder gains FDA RMAT designation
    Categories: Drug Discovery & Development
  • Passive cough monitoring linked to worsening asthma symptoms
    Categories: Digital & Data, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top